USPH · Earnings event · Q2 2026 · archived
U.S. Physical Therapy (USPH) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $0.75 vs estimate $0.84 (-11.2%) — classified MISS.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $0.84 | $0.75 | -11.2% |
| Revenue | — | — | — |
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated USPH Buy (Wait) at 4.8/10. After the Q2 2026 report, the verdict moved to Sell at 4.5/10.
Healthcare context
USPH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $1.21B
- P/E (fwd)
- 23.6
- P/E (ttm)
- 477.9
- 52-week range
- $58.19–$93.50
- Off 52-week high
- 13.1%
- RSI (14)
- 62
- Volume vs avg
- 1.40×
- Engine score
- 4.4/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.